Mitozantrone-induced onycholysis. A series of five cases

The anthracenedione cytotoxic agent, mitozantrone, has a well-established place in the treatment of acute leukaemia, lymphoma, breast carcinoma and other malignant tumours. In general it is well tolerated apart from myelosuppression and dose-related cardiotoxicity. Alopecia is a common side-effect with mitozantrone but otherwise the skin and its appendages are rarely affected. We present five cases of mitozantrone-induced onycholysis.